Related Experiment Video
Updated: May 30, 2026
LAD-Ligation: A Murine Model of Myocardial Infarction
Published on: October 14, 2009
LOX-1: a critical player in the genesis and progression of myocardial ischemia
1Department of Emergency Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. lvjingjun@gmail.com
Insights
Inhibition of Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) can reduce myocardial ischemia injury and cardiac remodeling. Targeting LOX-1 lessens oxidative stress and inflammation, improving cardiac function and survival.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Biomedical Science
Background:
- Myocardial ischemia is a leading cause of death globally.
- Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is implicated in atherosclerosis and ischemic heart disease.
- LOX-1 is a receptor for oxidized low-density lipoprotein (ox-LDL) in key cardiac cells.
Purpose of the Study:
- To investigate the role of LOX-1 in myocardial ischemia.
- To evaluate the therapeutic potential of LOX-1 inhibition in ischemic heart disease.
Main Methods:
- In vitro and in vivo studies were conducted.
- LOX-1 expression levels were monitored during acute and chronic ischemia.
- The effects of LOX-1 inhibition on myocardial injury, cardiac remodeling, oxidative stress, and inflammatory markers were assessed.
- Molecular signaling pathways, including redox-sensitive pathways and angiotensin II type 1 receptor expression, were analyzed.
Main Results:
- LOX-1 is upregulated during both acute and chronic myocardial ischemia.
- Inhibition of LOX-1 significantly reduces ischemic myocardial injury and limits cardiac remodeling.
- LOX-1 inhibition decreases oxidative stress and inflammatory responses.
- Molecular studies show reduced pro-inflammatory cytokine release and angiotensin II type 1 receptor expression via redox-sensitive pathway inhibition.
- These effects limit cardiomyocyte hypertrophy and collagen accumulation.
Conclusions:
- LOX-1 plays a critical role in the pathogenesis of myocardial ischemia.
- Inhibiting LOX-1 offers a promising therapeutic strategy to mitigate ischemic myocardial injury.
- LOX-1 inhibition improves cardiac function and enhances survival following ischemic events.
Abstract:
Myocardial ischemia is the most common cause of mortality and morbidity in the developed countries and rapidly becoming a common malady in the developing countries. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), encoded by the OLR1 gene, is a scavenger receptor that plays a fundamental role in the genesis and progression of atherosclerosis and its complications. LOX-1 has been identified as a major receptor for oxidized low-density lipoprotein (ox-LDL) in endothelial cells, cardiomyocytes and fibroblast. In vitro and in vivo studies show that LOX-1 is upregulated during acute myocardial ischemia, and continues to be upregulated during chronic ischemia. Further, LOX-1 inhibition reduces ischemic myocardial injury and limits cardiac remodeling. LOX-1 inhibition decreases oxidative stress and inflammatory response to injury resulting in limitation of ischemic injury. Molecular studies show that LOX-1 inhibition reduces release of pro-inflammatory cytokines and expression of angiotensin II type 1 receptor via inhibition of redox-sensitive pathways. These alterations limit cardiomyocyte hypertrophy and collagen accumulation in the ischemic regions. These alterations in molecular signaling and physical alterations can result in improved cardiac function and better survival after ischemic myocardial injury.
Related Concept Videos
01:21Myocarditis I: Introduction
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...